# Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

> **NCT03469479** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 252 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** FOLFOX
- **PROCEDURE:** Hepatic resection

## Key facts

- **NCT ID:** NCT03469479
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-02
- **Primary completion:** 2023-03-02
- **Final completion:** 2023-03-02
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469479, "Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03469479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*